De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide

Kevin C. Entzminger, Jeong Min Hyun, Robert J. Pantazes, Athena C. Patterson-Orazem, Ahlam N. Qerqez, Zach P. Frye, Randall A. Hughes, Andrew D. Ellington, Raquel L. Lieberman, Costas D. Maranas, Jennifer A. Maynard

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Computational antibody engineering efforts to date have focused on improving binding affinities or biophysical characteristics. De novo design of antibodies binding specific epitopes could greatly accelerate discovery of therapeutics as compared to conventional immunization or synthetic library selection strategies. Here, we employed de novo complementarity determining region (CDR) design to engineer targeted antibody-antigen interactions using previously described in silico methods. CDRs predicted to bind the minimal FLAG peptide (ASP-Tyr-Lys-ASP) were grafted onto a single-chain variable fragment (scFv) acceptor framework. Fifty scFvs comprised of designed heavy and light or just heavy chain CDRs were synthesized and screened for peptide binding by phage ELISA. Roughly half of the designs resulted in detectable scFv expression. Four antibodies, designed entirely in silico, bound the minimal FLAG sequence with high specificity and sensitivity. When reformatted as soluble antigen-binding fragments (Fab), these clones expressed well, were predominantly monomeric and retained peptide specificity. In both formats, the antibodies bind the peptide only when present at the amino-terminus of a carrier protein and even conservative peptide amino acid substitutions resulted in a complete loss of binding. These results support in silico CDR design of antibody specificity as an emerging antibody engineering strategy.

Original languageEnglish (US)
Article number10295
JournalScientific reports
Issue number1
StatePublished - Dec 1 2017

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide'. Together they form a unique fingerprint.

Cite this